Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU

(1) Hospital Universitario de La Princesa, IIS-IP and CIBERehd,Madrid,Spain

(2) Complexo Hospitalario Universitario de Santiago,Santiago de Compostela,Spain

(3) Hospital Universitario Reina Sofía and IMIBIC,Córdoba,Spain

(4) Hospital de Galdakao-Usansolo,Galdakao,Spain

(5) Hospital Universitario de Gran Canaria Dr. Negrín,Las Palmas,Spain

(6) Hospital Universitari Mutua Terrasa,Tarrasa,Spain

(7) Hospital San Pedro,Logroño,Spain

(8) Hospital Universitari Son Espases,Palma de Mallorca,Spain

(9) Hospital Clínico Universitario “Lozano Blesa”, IIS Aragón and CIBERehd,Zaragoza,Spain

(10) Hospital General Universitario de Ciudad Real,Ciudad Real,Spain

(11) Hospital Universitari i Politecnic La Fe and CIBERehd,Valencia,Spain

(12) Hospital Universitario Central de Asturias and ISPA,Oviedo,Spain

(13) Hospital Universitario Marqués de Valdecilla,Santander,Spain

(14) Hospital Universitario San Pedro de Alcántara,Cáceres,Spain

(15) Complejo Hospitalario de Navarra,Pamplona,Spain

(16) Hospital Universitario de Burgos,Burgos,Spain

(17) Hospital General Universitario J.M. Morales Meseguer,Murcia,Spain

(18) Universidad Autónoma de Madrid/IdiPaz and CIBERESP,Madrid,Spain



This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019